已收录 268921 条政策
 政策提纲
  • 暂无提纲
At the Bench: Preclinical rationale for CTLA‐4 and PD‐1 blockade as cancer immunotherapy
[摘要] Tumorscanavoidimmunesurveillancebystimulatingimmuneinhibitoryreceptorsthatfunctiontoturnoffestablishedimmuneresponses.ByblockingtheabilityoftumorstostimulateinhibitoryreceptorsonTcells,sustained,anti‐tumorimmuneresponsescanbegeneratedinanimals.Thus,therapeuticblockadeofimmuneinhibitorycheckpointsprovidesapotentialmethodtoboostanti‐tumorimmunity.TheCTLA‐4andPD‐1RsrepresenttwoTcell‐inhibitoryreceptorswithindependentmechanismsofaction.PreclinicalinvestigationsrevealedthatCTLA‐4enforcesanactivationthresholdandattenuatesproliferationoftumor‐specificTlymphocytes.Incontrast,PD‐1functionsprimarilyasastopsignalthatlimitsTcelleffectorfunctionwithinatumor.TheuniquemechanismsandsitesofactionofCTLA‐4andPD‐1suggestthatalthoughblockadeofeitherhasthepotentialtopromoteanti‐tumorimmuneresponses,combinedblockadeofbothmightofferevenmorepotentanti‐tumoractivity.SeerelatedreviewAttheBedside:CTLA‐4andPD‐1blockingantibodiesincancerimmunotherapy...
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 生理学
[关键词] tumor;receptor;inhibitory;coinhibitory;costimulatory;costimulation;PD‐L1;ipilimumab [时效性] 
   浏览次数:18      统一登录查看全文      激活码登录查看全文